Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma
- PMID: 16985695
- PMCID: PMC1476038
Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma
Abstract
The search continues for better tumor markers to improve the rate of detection of transitional cell carcinoma (TCC) more quickly in larger populations and to predict the possibility of disease recurrence. Among several new tests currently being screened, telomerase and hyaluronic acid/hyaluronidase (HA/HAase) have shown sensitivity and specificity equal to or better than cytology, and other promising tumor markers are being investigated. Although no marker has yet replaced the need to perform cystoscopy and cytology, the new tests can minimize the cost and difficulty of screening and long-term surveillance of patients who have or are at risk for bladder cancer.
Similar articles
-
Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade.J Urol. 2000 Jan;163(1):348-56. doi: 10.1016/s0022-5347(05)68050-0. J Urol. 2000. PMID: 10604388
-
Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.Eur Urol. 2004 Oct;46(4):466-71. doi: 10.1016/j.eururo.2004.06.006. Eur Urol. 2004. PMID: 15363562
-
[Molecular markers for transitional cell carcinoma of bladder].Harefuah. 2003 Jul;142(7):531-5, 565. Harefuah. 2003. PMID: 12908389 Review. Hebrew.
-
Urine cytology. It is still the gold standard for screening?Urol Clin North Am. 2000 Feb;27(1):25-37. doi: 10.1016/s0094-0143(05)70231-7. Urol Clin North Am. 2000. PMID: 10696242 Review.
-
Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise.Indian J Urol. 2015 Oct-Dec;31(4):273-82. doi: 10.4103/0970-1591.166448. Indian J Urol. 2015. PMID: 26604437 Free PMC article. Review.
Cited by
-
Companied P16 genetic and protein status together providing useful information on the clinical outcome of urinary bladder cancer.Medicine (Baltimore). 2018 Apr;97(15):e0353. doi: 10.1097/MD.0000000000010353. Medicine (Baltimore). 2018. PMID: 29642177 Free PMC article.
-
Cell-free lncRNA expression signatures in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer.J Cell Mol Med. 2018 May;22(5):2838-2845. doi: 10.1111/jcmm.13578. Epub 2018 Mar 8. J Cell Mol Med. 2018. PMID: 29516641 Free PMC article.
-
Immunoscreening of urinary bladder cancer cDNA library and identification of potential tumor antigen.World J Urol. 2009 Feb;27(1):107-12. doi: 10.1007/s00345-008-0326-4. Epub 2008 Oct 1. World J Urol. 2009. PMID: 18828023
-
CK20 and Ki-67 as significant prognostic factors in human bladder carcinoma.Clin Exp Med. 2010 Sep;10(3):153-8. doi: 10.1007/s10238-009-0088-3. Epub 2010 Jan 13. Clin Exp Med. 2010. PMID: 20069333
-
A Quest for Accuracy: Evaluation of The Paris System in Diagnosis of Urothelial Carcinomas.J Cytol. 2019 Jul-Sep;36(3):169-173. doi: 10.4103/JOC.JOC_67_18. J Cytol. 2019. PMID: 31359918 Free PMC article.
References
-
- Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7–33. - PubMed
-
- Messing EM, Young TB, Hunt VB, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology. 1995;45:387–396. - PubMed
-
- Kroft SH, Oyasu R. Urinary bladder cancer: Mechanisms of development and progression. Lab Invest. 1994;1:158–174. - PubMed
-
- Henry NM. Natural history of bladder cancer. Urol Clin North Am. 1992;19:429. - PubMed
-
- de Vere White RW, Stapp E. Predicting prognosis in patients with superficial bladder cancer. Oncology. 1998;12:1717–1723. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources